Balkan nephropathy

disease
On this page

Also known as AANaristolochic acid nephropathyBalkan endemic nephropathyBENChinese herb endemic nephropathyDanubian endemic familial nephropathyDEFNendemic nephropathy

Summary

Balkan nephropathy (MONDO:0007416) is a disease. A subtype of interstitial nephritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameBalkan nephropathy
Mondo IDMONDO:0007416
EFOEFO:0007164
MeSHD001449
OMIM124100
DOIDDOID:3052
ICD-10-CMN15.0
ICD-1118497836
NCITC123025
SNOMED CT26121002
UMLSC0004698
MedGen495
GARD0008576
Is cancer (heuristic)no

Also known as: AAN · aristolochic acid nephropathy · Balkan endemic nephropathy · BEN · Chinese herb endemic nephropathy · Danubian endemic familial nephropathy · DEFN · endemic nephropathy

Disease family

This is a subtype of interstitial nephritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorderkidney disordernephritisinterstitial nephritisBalkan nephropathy

Related subtypes (1): karyomegalic interstitial nephritis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.